ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0417

Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study

Rula Hajj-Ali1, Robert Butler2, Carol Langford3, Leonard Calabrese2, David Cuthbertson4, Nader Khalidi5, CURRY LEE MD KOENING6, Carol McAlear7, Paul Monach8, Larry Moreland9, Christian Pagnoux10, Philip Seo11, Ulrich Specks12, Antoine Sreih7, Kenneth Warrington13 and Peter Merkel7, 1Cleveland Clinic, Hunting Valley, OH, 2Cleveland Clinic, Cleveland, OH, 3Cleveland Clinic, Moreland Hills, OH, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, 7University of Pennsylvania, Philadelphia, PA, 8Brigham and Women's Hospital, Boston, MA, 9University of Colorado, Denver, CO, 10Mount Sinai Hospital, Toronto, ON, Canada, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, Rochester, MN, 13Mayo Clinic, Rochester, Minnesota

Meeting: ACR Convergence 2021

Keywords: , ,

Session Information

Date: Saturday, November 6, 2021

Session Title: Vasculitis – ANCA-Associated Poster (0414–0436)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The prevalence of neurologic involvement (NI) in ANCA-associated vasculitis (AAV), especially central nervous system (CNS) involvement, is not well characterized. This project aimed to describe the prevalence and types of peripheral nervous system (PNS) NI and CNS NI in AAV, and associations of NI with other manifestation of vasculitis.

Methods: Analysis of patients with AAV [granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic granulomatosis with polyangiitis (EGPA)] participating in a multicenter longitudinal observational study. Data were from 2006-2021 from patients at least 18 years old at enrollment. Standardized forms were used to document patient demographics, disease type, organ involvement, and ANCA status. Patient subsets were compared according to presence or absence of NI.

Results: Data from 1368 patients were available: 470 (34%) had NI (Figure 1) of whom 216 (46%) had GPA, 37 (7.8%) had MPA, and 217 (46.2%) had EGPA. The prevalence of NI was 24.8% (216/869) in GPA, 22% (37/170) in MPA, and 67% (217/326) in EGPA. The prevalence of CNS NI in the total cohort was 47/1368 (3.4%) and the prevalence of PNS NI was 374/1368 (27.3%), with 44 patients (3.2%) having NI that was not classified. GPA was the most common diagnosis in patients with CNS NI (78% compared to 2% in MPA and 19% in EGPA). For PNS NI, EGPA was the most common diagnosis (51% compared to 40% in GPA and 8.8% in MPA).

Patient sex and race did not differ between patients with or without NI. Patients with NI were 53% female and 47% male, 88.7% were White, 1.5 % Black, 3.2% Hispanic, and 4.8% Asian. Mean age at diagnosis of patients with NI was higher than patients without NI (51.4 vs 47.0 years, p <0.001). NI was associated with skin (49.4% vs. 29.5%, p < 0.001), venous thrombosis (12.8% vs. 8.6%, p= 0.016), and cardiovascular (15.5% vs. 7.2%, p < 0.001) involvement. Patients with NI were less likely to have renal (45.6% vs. 55.9%, p < 0.001), and eye (20 % vs. 28%, p < 0.001) involvement. NI was associated with skin and kidney involvement in EGPA, musculoskeletal, skin, kidney, venous thromboses in GPA and constitutional and musculoskeletal symptoms in MPA (Figure 2).

Patients with NI were more likely to have P-ANCA pattern (43.1 % vs 31.2 % p =0008) and anti-MPO (44.4% vs 30% p < .0001) than patients with no NI.

Conclusion: NI in AAV is common, occurring in approximately one-third of patients, and was most common in EGPA, compared to GPA or MPA. CNS NI occurs more commonly in GPA. NI is associated with various specific organ systems and P-ANCA/anti MPO positivity. These data are informative for clinicians and patients with AAV, and should raise the awareness of this common manifestation of vasculitis. The relationships of NI with other specific manifestations of disease warrants additional study.

Figure 1. Prevalence of neurologic involvement (NI) in patients with ANCA-associated vasculitis

Figure 2. Organ involvement with patient with ANCA-associated vasculitis with and without neurologic involvement (NI) by disease

Disclosures: R. Hajj-Ali, Novartis, 6, Rockpointe, INC., 6, Projects In Knowledge, 6, UpToDate, 9; R. Butler, None; C. Langford, None; L. Calabrese, Lilly, 2, BMS, 2, Genentech, 2; D. Cuthbertson, None; N. Khalidi, Roche, 12, Advisory Board for GCA CME November 2020, BMS, 12, Clinical Trial (Investigator Initiated- BMS supplied drug only, no fees received from BMS), Sanofi, 12, Clinical Trial 2020 GCA and PMR, Abbvie, 12, Clinical Trial 2020-2021 GCA; C. KOENING, None; C. McAlear, None; P. Monach, Kiniksa, 1, Celgene, 2, Chemocentryx, 1; L. Moreland, None; C. Pagnoux, Gsk, 2, 5, 6, Roche, 2, 5, 6, Otuska, 2, Pfizer, 5, 6, Chemocentryx, 2, Astrazeneca, 1; P. Seo, Amgen, 1, Janssen, 1; U. Specks, ChemoCentryx, 2, 5, Genentech, 5, Bristo-Myer Squibb, 5, InflxRX, 5, Astra Zeneca, 1, 5, GSK, 5; A. Sreih, Bristol Myers Squibb, 3, Alexion, 11; K. Warrington, Eli Lilly, 5, Kiniksa, 5; P. Merkel, AbbVie, 2, 5, AstraZeneca, 2, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 2, EMDSerono, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Magenta, 2, Neutrolis, 2, Novartis, 2, Pfizer, 2, Sanofi, 5, Star Therapeutics, 2, Takeda, 2, Talaris, 2, UpToDate, 9.

To cite this abstract in AMA style:

Hajj-Ali R, Butler R, Langford C, Calabrese L, Cuthbertson D, Khalidi N, KOENING C, McAlear C, Monach P, Moreland L, Pagnoux C, Seo P, Specks U, Sreih A, Warrington K, Merkel P. Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/neurologic-involvement-in-anca-associated-vasculitis-data-from-multicenter-longitudinal-observational-study/. Accessed February 3, 2023.

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neurologic-involvement-in-anca-associated-vasculitis-data-from-multicenter-longitudinal-observational-study/